financetom
Business
financetom
/
Business
/
GDS Holdings' Q4 Loss Widens, Revenue Rises; Provides 2024 Revenue Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GDS Holdings' Q4 Loss Widens, Revenue Rises; Provides 2024 Revenue Outlook
Mar 26, 2024 6:21 AM

08:46 AM EDT, 03/26/2024 (MT Newswires) -- GDS Holdings ( GDS ) reported a Q4 loss Tuesday of 2.16 renminbi ($0.30) per diluted share, wider than its loss of 0.13 renminbi a year earlier.

Analysts polled by Capital IQ expected a loss of 3.50 renminbi.

Revenue for the quarter ended Dec. 31 was 2.56 billion renminbi, up from 2.40 billion renminbi a year earlier.

Analysts surveyed by Capital IQ expected 2.58 billion renminbi.

For 2024, the Chinese data center operator expects revenue of 11.34 billion renminbi to 11.76 billion renminbi. Analysts polled by Capital IQ expect a 11.14 billion renminbi.

Shares of the company were down 2% in Tuesday's premarket activity.

Price: 8.18, Change: -0.19, Percent Change: -2.27

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Calidi Biotherapeutics (CLDI) Shares Are Down Over 50%
Why Calidi Biotherapeutics (CLDI) Shares Are Down Over 50%
Apr 16, 2024
Calidi Biotherapeutics Inc ( CLDI ) shares are trading lower by 59% to $0.25 during Tuesday’s session after the company announced the pricing of a $6.1 million public offering. The offering includes various types of warrants with different exercise prices and expiration dates. The company plans to use the net proceeds for working capital, general corporate purposes, and pre-clinical and...
Why Palisade Bio Stock Is Soaring Today
Why Palisade Bio Stock Is Soaring Today
Apr 16, 2024
Palisade Bio, Inc. ( PALI ) shares are trading higher Tuesday after the company announced the completion of its analysis evaluating ex-vivo bioactivation of PALI-2108. The Details: Palisade Bio ( PALI ) said the findings demonstrated PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with ulcerative colitis...
Why Jaguar Health Stock Is Up Today
Why Jaguar Health Stock Is Up Today
Apr 16, 2024
Jaguar Health, Inc. ( JAGX ) shares are trading higher Tuesday after the company announced it has signed an exclusive 5-year in-license agreement with Venture Life Group PLC. The Details: The license agreement is for the U.S. market for Venture Life's FDA-approved prescription product, Gelclair. Gelclair is used for the treatment of oral mucositis, also called “chemo mouth.”  “We are...
Chile must pass permitting reforms to unblock investment: BHP
Chile must pass permitting reforms to unblock investment: BHP
Apr 16, 2024
SANTIAGO, April 16 (Reuters) - Chile's government needs to quickly approve a proposal to streamline permitting for the mining industry to unlock and promote investment in the world's top copper-producing country, a top BHP official said on Tuesday In Chile it is urgent to improve the permit system to allow companies to approve large investment projects in a timely manner,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved